# US 11,993,658 B2 · Anti-BCMA antibodies and treatment methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,993,658 B2
- Document ID: US11993658B2
- Status: Granted
- Kind: B2
- Application number: 17/041,349
- Filed: 2019-03-25
- Published: 2021-05-06
- Granted: 2024-05-28
- Earliest claimed: 2018-03-26
- Assignees: Sutro Biopharma, Inc.
- Applicants: Sutro Biopharma, Inc.
- Inventors: Alice Yam; Ryan Stafford; Xiaofan Li; Junhao Yang; Stephanie Armstrong; Abigail Yu
- Web page: https://patentgrep.com/patent/US11993658B2

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61P 35/00: Antineoplastic agents
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to antibodies that selectively bind to B-cell maturation antigen (BCMA) and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

## Claims

### Claim 1

An isolated antibody of the IgG class that specifically binds to B-cell maturation antigen (BCMA), wherein the antibody comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-LI, a CDR-L2, and a CDR-L3, of the VH-VL (heavy chain variable region-light chain variable region) pair of SEQ ID NO: 170 and 217.

### Claim 2 (depends on 1)

The antibody of claim 1 comprising a VH region of SEQ ID NO: 170, or a variant thereof having 20 or fewer amino acid substitutions, and a VL region of SEQ ID NO: 217, or a variant thereof having 20 or fewer amino acid substitutions.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the antibody comprises at least one constant region domain selected from SEQ ID NO: 239-242.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein the antibody is humanized.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein the antibody is aglycosylated.

### Claim 6 (depends on 1)

The antibody of claim 1, wherein the antibody is an antibody fragment.

### Claim 7 (depends on 6)

The antibody of claim 6, wherein the antibody fragment is selected from an FIT fragment, a Fab fragment, a F(ab′)2 fragment, a Fab′ fragment, an scFv (sFv) fragment, and an scFv-Fc fragment.

### Claim 8 (depends on 7)

The antibody of claim 7, wherein the antibody is an scFv fragment.

### Claim 9 (depends on 1)

The antibody of claim 1 that specifically binds to B-cell maturation antigen (BCMA), wherein the antibody comprises:
a VH comprising: a CDR-H1 comprising one of SEQ ID NO: 8 and 34; a CDR-H2 comprising one of SEQ ID NO: 57 and 79; and a CDR-H3 comprising SEQ ID NO: 119.

### Claim 10 (depends on 9)

The antibody of claim 9, wherein the antibody comprises:
(a) a VL comprising: a CDR-L1 comprising SEQ ID NO: 146; a CDR-L2 comprising SEQ ID NO: 155; and a CDR-L3 comprising SEQ ID NO: 161.

### Claim 11 (depends on 9)

The antibody of claim 9, wherein the antibody comprises:
a VH comprising: a CDR-H1 comprising one of SEQ ID NO: 8 and 34; a CDR-H2 comprising one of SEQ ID NO: 57 and 79; a CDR-H3 comprising SEQ ID NO: 119; a CDR-L1 comprising SEQ ID NO: 146; a CDR-L2 comprising SEQ ID NO: 155; and a CDR-L3 comprising SEQ ID NO: 161.

### Claim 12 (depends on 9)

The antibody of claim 9, wherein the antibody has a ka of about 4.57×105 M−1×sec−1 to about 7.66×105 M−1×sec−1 when associating with human BCMA at a temperature of 25° C.

### Claim 13 (depends on 1)

A kit comprising an antibody of claim 1, and instructions for use of the antibody.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1, 14)

A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of an antibody of claim 1, or a pharmaceutical composition of claim 14, wherein the disease or condition is a BCMA-expressing cancer.

### Claim 16 (depends on 15)

The method of claim 15, the BCMA-expressing cancer is leukemia, lymphoma, multiple myeloma, a plasmacytoid dendritic cell tumor, a B-cell lineage malignancy, or a plasma cell neoplasm, and optionally wherein the lymphoma is diffuse large B-cell lymophoma (DLBCL), a low-grade B-cell lymphoma, Burkitt's lymphoma, a plasmablastic lymphoma, or a follicular lymphoma.